The Battle for Lung Cancer Therapies: A Look at the Success of Third-Generation EGFR Inhibitors

The global sales of third-generation EGFR inhibitors, with AstraZeneca's flagship lung cancer drug Osimertinib as the representative, have reached new heights in 2023, with expectations of surpassing $6 billion. However, other players in the lung cancer drug race are determined not to lag behind. Recently, Johnson & Johnson highlighted during an investor day that its EGFR/c-Met bispecific antibody, AvenTuza (evantuxumab), has a peak sales potential of $5 billion in combination therapy for lung diseases, with a market share target of 50% in first-line treatment.

The Emerging War in the Lung Cancer Drug Arena:
This announcement has sparked ripples akin to a stone cast onto a calm lake. A quiet war is brewing in the field of lung cancer therapeutics, with AstraZeneca and Johnson & Johnson leading the charge. Roche, Eli Lilly, and Daiichi Sankyo have also joined the fray, signaling a potential iteration of the "lung cancer innovation drug champions."

Understanding Lung Cancer Medications:
Common medications for lung cancer include immunotherapies and targeted therapies, with Keytruda (pembrolizumab) and Opdivo (nivolumab) representing immunotherapies, and Osimertinib as a top-selling EGFR inhibitor in the targeted therapy category.

Osimertinib's Success and Approval:
Osimertinib, developed by AstraZeneca, was the first successful third-generation EGFR inhibitor to enter the market. It received accelerated FDA approval in 2015 and was subsequently approved as a first-line treatment for metastatic NSCLC patients with EGFR mutations (Ex19del or L858R) on April 19, 2018.

Global Approval and Indications:
To date, Osimertinib has been approved as a monotherapy in over 100 countries and regions, including the United States, European Union, China, and Japan. It is used for the first-line treatment of locally advanced or metastatic EGFRmNSCLC, locally advanced or metastatic NSCLC patients with positive EGFRT790M mutations, and as adjuvant therapy for early-stage (IB, II, and IIIA) EGFRmNSCLC.

Unparalleled Efficacy and Further Advancements:
Osimertinib is the only targeted therapy to demonstrate improved disease-free survival in early-stage EGFR-mutated lung cancer patients in the ADAURA Phase III trial and improved overall survival in advanced-stage disease in the FLAURA Phase III trial.

Positive Results in FLAURA2 Trial:
On October 21st of this year, the FLAURA2 Phase III trial of Osimertinib yielded positive results. When compared to Osimertinib monotherapy, the combination of Osimertinib and chemotherapy improved central nervous system progression-free survival (PFS) by 42% in NSCLC patients with EGFR-mutated brain metastases. The trial's two-year follow-up demonstrated that 74% of patients receiving Osimertinib plus chemotherapy experienced no central nervous system disease progression or death, compared to 54% of patients receiving Osimertinib monotherapy. The combination therapy also showed a higher complete CNS response rate (CR) of 59% compared to Osimertinib monotherapy (43%).

Expanding Research and Future Prospects:
As the current best-selling targeted therapy for lung cancer, Osimertinib continues to develop other combination and adjuvant therapies. AstraZeneca is conducting Phase III trials such as ADAURA2 for adjuvant resectable disease (IA2-IA3 stage), NeoADAURA for neoadjuvant therapy, and LAURA for locally advanced unresectable disease. Additionally, AstraZeneca is exploring the combination of Osimertinib with MET inhibitors like Savolitinib through the SAVANNAH and ORCHARD Phase II trials, as well as other potential new drugs through the SAFFRON Phase III trial to study mechanisms of overcoming tumor resistance.

Market Success and Future Outlook:
Since its launch, Osimertinib's sales have steadily increased, particularly after its approval as a first-line therapy in 2018. In 2021, its sales exceeded $5 billion for the first time, solidifying its position as AstraZeneca's flagship oncology drug. As of the first nine months of this year, Osimertinib's sales have already reached $4.38 billion, with expectations of surpassing $6 billion for the full year.

The field of lung cancer therapeutics is witnessing an intense battle for dominance, with AstraZeneca's Osimertinib and Johnson & Johnson's AvenTuza leading the charge. As other major pharmaceutical companies enter thearena, the development of third-generation EGFR inhibitors and combination therapies is gaining momentum. Osimertinib's success as a targeted therapy for EGFR-mutated lung cancer has set a high bar for efficacy and has expanded its indications over time. Ongoing research and clinical trials aim to further optimize the use of Osimertinib and explore its potential in adjuvant and neoadjuvant settings, as well as in combination with other targeted agents.

The market success of Osimertinib is evident in its growing sales, surpassing $5 billion in 2021 and expected to exceed $6 billion in 2023. However, with Johnson & Johnson's AvenTuza entering the scene with its bispecific antibody, the competition in the lung cancer drug market is intensifying. Other major pharmaceutical companies are also investing in research and development to secure their position in this lucrative field.

The advancements in lung cancer therapies, particularly in the realm of EGFR inhibitors, bring hope to patients and healthcare professionals alike. As the battle for lung cancer therapies continues, patients can anticipate more treatment options and improved outcomes in the fight against this devastating disease.